Edwards Lifesciences Corporation
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.44B | $2.96B | $2.49B | $2.32B | $2.05B | $1.90B | $1.68B | $1.45B |
| Cost of Revenue | $875.3M | $797.4M | $617.2M | $625.6M | $516.6M | $491.0M | $489.8M | $408.3M |
| Gross Profit | $2.56B | $2.17B | $1.88B | $1.70B | $1.53B | $1.41B | $1.19B | $1.04B |
| Gross Margin | 74.5% | 73.1% | 75.2% | 73.1% | 74.7% | 74.2% | 70.8% | 71.8% |
| Operating Expenses | ||||||||
| Research & Development | $552.6M | $442.2M | $382.9M | $346.5M | $323.0M | $291.3M | $246.3M | $204.4M |
| SG&A Expense | $990.8M | $904.7M | $850.7M | $858.0M | $733.4M | $697.4M | $642.4M | $550.0M |
| Operating Income | $1.09B | $751.2M | $639.6M | $1.16B | $521.0M | $392.6M | $286.7M | $270.6M |
| Operating Margin | 31.7% | 25.3% | 25.6% | 50.0% | 25.5% | 20.7% | 17.1% | 18.7% |
| Interest Expense | $23.2M | $19.2M | $17.2M | $17.2M | $9.8M | $4.4M | $3.1M | $2.4M |
| Pretax Income | $1.03B | $737.9M | $622.4M | $1.14B | $511.2M | $388.2M | $283.6M | $268.2M |
| Income Tax Expense | $451.3M | $168.4M | $127.5M | $332.9M | $122.1M | $96.7M | $46.9M | $50.2M |
| Net Income | $583.6M | $569.5M | $494.9M | $811.1M | $389.1M | $291.5M | $236.7M | $218.0M |
| Net Margin | 17.0% | 19.2% | 19.8% | 34.9% | 19.0% | 15.3% | 14.1% | 15.1% |
| EPS (Basic) | $0.92 | $0.89 | $0.77 | $1.27 | $0.58 | $0.85 | $0.69 | $0.64 |
| EPS (Diluted) | $0.90 | $0.87 | $0.75 | $1.25 | $0.57 | $0.82 | $0.66 | $0.61 |
| Shares Outstanding (Basic) | 632.7M | 639.0M | 646.5M | 639.0M | 670.2M | 344.7M | 343.8M | 341.1M |
| Shares Outstanding (Diluted) | 647.7M | 653.4M | 660.9M | 651.0M | 682.8M | 354.9M | 358.2M | 357.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |